Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL

Next Previous
Trial Profile

A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MOLTO

Most Recent Events

  • 15 Jun 2023 Results (n=28) evaluating the activity and safety of atezolizumab, venetoclax , obinutuzumab combination in treatment naive patients with DLBCL variant of RS, presented at the 28th Congress of the European Haematology Association
  • 06 Jun 2023 Primary endpoint (Efficacy of the combination venetoclax, obinutuzumab and atezolizumab in terms of Overall Response Rate (ORR)) has been met, as per results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 06 Jun 2023 Results (n=28; enrolled from Oct 2019 to Oct 2022) assessing the activity and safety of atezolizumab, venetoclax and obinutuzumab combination in untreated diffuse large B-cell lymphoma-Richter syndrome, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top